Medtronic gets FDA OK for next-gen glucose monitoring system

The FDA has cleared Medtronic's ($MDT) iPro 2, a next generation professional continuous glucose monitoring system. "My vision is to make an iPro2 evaluation part of routine visits for many of my patients with diabetes. I find it particularly helpful in identifying repeated glucose lows at night and glucose highs after meals, issues that a near-normal A1C does not reveal," said Dr. David Huffman of University Diabetes and Endocrine Consultants. Medtronic release

Suggested Articles

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.

A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.